- Iveric bio ( NASDAQ: ISEE ) signed a license agreement for the right to develop and commercialize new formulations of eye disorder drug candidate Zimura using DelSiTech's silica-based sustained release technology.
- Under the agreement, Iveric will pay DelSiTech €1.25M upfront and development and commercial milestones plus royalties on net sales of products.
- Iveric said that as part of its lifecycle expansion plan for Zimura, it is committed to developing sustained release technologies to treat age-related macular degeneration (AMD) and that these technologies could potentially address patients being treated for geographic atrophy (GA) and intermediate AMD.
- Iveric said it expects data from a second phase 3 trial, dubbed GATHER2, of Zimura for GA in Q3 2022 and if results are positive it will file for U.S. and EU approval of of Zimura for GA. The study called GATHER1 had already met its main efficacy goal, according to the company.
- The company also plans to explore Zimura in earlier stages of AMD by starting a trial evaluating the current formulation of Zimura in patients with intermediate AMD in Q4 2022.
- ISEE +1.49% to $9.54 premarket July 5
For further details see:
Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura